Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

被引：3

作者：

Furman, Richard R. ^{[1
]}

Wierda, William G. ^{[2
]}

Schuh, Anna ^{[3
]}

Devereux, Stephen ^{[4
]}

Chaves, Jorge M. ^{[5
]}

Brown, Jennifer R. ^{[6
]}

Hillmen, Peter ^{[7
]}

Martin, Peter ^{[8
]}

Awan, Farrukh T. ^{[9
]}

Stephens, Deborah M. ^{[10
]}

Ghia, Paolo ^{[11
,12
]}

Barrientos, Jacqueline C. ^{[13
]}

Pagel, John M. ^{[14
]}

Woyach, Jennifer ^{[15
]}

Burke, Kathleen ^{[16
]}

Covey, Todd ^{[17
]}

Gulrajani, Michael ^{[18
]}

Hamdy, Ahmed ^{[18
]}

Izumi, Raquel ^{[18
]}

Frigault, Melanie M. ^{[18
]}

Patel, Priti ^{[18
]}

Rothbaum, Wayne ^{[18
]}

Wang, Min Hui ^{[18
]}

O'Brien, Susan M. ^{[19
]}

Byrd, John C. ^{[15
]}

机构：

[1] Weill Cornell Med, New York, NY USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Univ Oxford, Dept Oncol, Oxford, England

[4] NHS Fdn Trust, Kings Coll Hosp, London, England

[5] Northwest Med Specialties PLLC, Tacoma, WA USA

[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[7] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[8] Weill Cornell Med New York Presbyterian Hosp, New York, NY USA

[9] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA

[10] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[11] Univ Vita Salute San Raffaele, Milan, Italy

[12] IRCCS San Raffaele Sci Inst, Milan, Italy

[13] Hofstra Northwell Sch Med, Hempstead, NY USA

[14] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA

[15] Ohio State Univ, Columbus, OH 43210 USA

[16] Oncol iMED AstraZeneca, Boston, MA USA

[17] Acerta Pharma, San Francisco, CA USA

[18] Acerta Pharma, San Francisco, CA USA

[19] UC Irvine, Chao Family Comprehens Canc Ctr, Orange, CA USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-128706

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3039

引用

页数：5

共 50 条

[31] Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Amrein, Philip C.
Attar, Eyal C.
Takvorian, Tak
Hochberg, Ephraim P.
Ballen, Karen K.
Leahy, Kathleen M.
Fisher, David C.
LaCasce, Ann S.
Jacobsen, Eric D.
Armand, Philippe
Hasserjian, Robert P.
Werner, Lillian
Neuberg, Donna
Brown, Jennifer R.
CLINICAL CANCER RESEARCH, 2011, 17 (09) : 2977 - 2986
[32] Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.
Jurczak, Wojciech
Pluta, Andrzej
Wach, Malgorzata
Lysak, Daniel
Simkovic, Martin
Kriachok, Iryna
Illes, Arpad
De la Serna, Javier
Dolan, Sean
Campbell, Philip
Musuraca, Gerardo
Jacob, Abraham
Avery, Eric Joseph
Lee, Jae Hoon
Usenko, Ganna
Wang, Min Hui
Yu, Ting
Ghia, Paolo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[33] Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
Xu, Wei
Song, Yongping
Wang, Tingyu
Yang, Shenmiao
Liu, Lihong
Hu, Yu
Zhang, Wei
Zhou, Jianfeng
Gao, Sujun
Ding, Kaiyang
Zhang, Huilai
Zhu, Zunmin
Wang, Shun-Qing
Xu, Bing
Hu, Jianda
Liu, Ting
Ji, Chunyan
Xia, Zhongjun
Li, Yan
Wang, Xin
Zhu, Huaqiang
Zhao, Renbin
Zhang, Bin
Xu, Zhixin
Li, Jianyong
BLOOD, 2020, 136
[34] Genasense (Bcl-2 antisense) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Phase 1 and 2 results.
Rai, KR
O'Brien, S
Cunningham, C
Turkina, AG
Ochoa, L
Frankel, SR
Golenkov, AK
BLOOD, 2002, 100 (11) : 384A - 384A
[35] Phase 1/2 results of ceralasertib (Cerala) as monotherapy or in combination with acalabrutinib (Acala) in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
Jurczak, Wojciech
Elmusharaf, Nagah
Fox, Christopher P.
Townsend, William
Paulovich, Amanda G.
Sharma, Shringi
Parr, Graeme
Munugalavadla, Veerendra
Krantz, Fanny
Yang, Helen
Dean, Emma
Manwani, Richa
Hillmen, Peter
CANCER RESEARCH, 2022, 82 (12)
[36] 42-month preliminary follow-up of the silastic ring vertical banded gastroplasty
Stoner, J
Stoner, P
Sytsma, J
OBESITY SURGERY, 1997, 7 (06) : 513 - 515
[37] Recurrent trauma histories of two 'unlucky teeth':: 42-month follow-up
Kirzioglu, Zuhal
Erturk, M. Semra Ozay
Altun, A. Ceren
DENTAL TRAUMATOLOGY, 2008, 24 (05) : E42 - E46
[38] 42-Month Preliminary Follow-up of the Silastic Ring Vertical Banded Gastroplasty
John Stoner
Patricia Stoner
Janet Sytsma
Obesity Surgery, 1997, 7 : 513 - 515
[39] Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
Woyach, Jennifer A.
Blachly, James S.
Rogers, Kerry A.
Bhat, Seema A.
Grever, Michael R.
Kittai, Adam S.
Jianfar, Mojgan
Lozanski, Gerard
Weiss, David M.
Andersen, Barbara L.
Patel, Priti
Munugalavadla, Veerendra
Butturini, Anna
Xu, Yan
Wang, Min Hui
Byrd, John C.
BLOOD, 2020, 136
[40] Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 10

← 1 2 3 4 5 →